No Photo Available

Last Update

2017-01-16T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Kate Bingham?

Ms. Kate Bingham

Managing Partner

SV Life Sciences

Direct Phone: +44 ** **** ****       

Email: k***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

SV Life Sciences

One Boston Place 201 Washington Street

Boston, Massachusetts 02108

United States

Company Description

SV Life Sciences is a leading, international healthcare venture capital firm. SVLS affiliated funds have been investing in healthcare companies since the early 1980s and the Firm closed its first dedicated life sciences fund in 1994. SVLS' team of 35 prof ... more

Find other employees at this company (70)

Background Information

Employment History

Position, Business Development

Vertex Pharmaceuticals Incorporated

Head of Technology Media and Telecoms Department

Denton Wilde Sapte LLP

Partner

SNR Denton

Affiliations

Board Member
Kesios Therapeutics Limited

Advisory Board Member
Medcity

Board Member
Autifony Therapeutics Limited

Board Member
Autifony Therapeutics Limited

Board Member
Pulmocide LTD

Investment Committee As Well As the Investment Committees for Al SV's Funds
DDF

Board Member
Calchan Limited

Board Member
Bicycle Therapeutics Limited

ADVISORY BOARD Member
MedCity Limited

Board Member
RespiVert LTD

Council Member
British Venture Capital Association

Board Member
Affibody AB

Board Member
Trine Pharmaceuticals , Inc.

Member, Supervisory Board
Ingenium Pharmaceuticals GmbH

Board Member
Dynogen Pharmaceuticals , Inc.

Board Member
PowderMed Ltd

Board Member
Nexans SA

Board Member
Metris

Board Member
MedNova

Board Member
LeukoSite

Board Member
Hexagen

Board Member
Cobra

Education

Biochemistry

Oxford University

MBA

Harvard Business School

Masters degree

Biochemistry

Oxford University

first class Masters degree

Biochemistry

University Oxford

first class degree

Biochemistry

Oxford University

Web References (139 Total References)


Kate Bingham Managing ...

www.consilium-comms.com [cached]

Kate Bingham Managing Partner of SV Life Sciences


“For sure there is funding for good deals� - views from the front line of life sciences venture capital - Medcity

www.medcityhq.com [cached]

Interview with Kate Bingham, Managing Partner at SV Life Sciences and a member of MedCity's advisory board

Kate Bingham is upbeat about the environment for biotech entrepreneurs in London and the greater south east, though she is clear that there is still work to be done.
"We do have cash, and good deals generally get funding," she says.
...
"Entrepreneurs could sometimes do better," Kate says.
...
"The problem with many plans is that they are unrealistic," Kate advises. "They have got to be fundable, and the more highly cost-efficient the approach is, the better I like it. Companies that estimate five years to clinical trials will not be funded because investors just can't take that level of uncertainty. The usual investment period is five to seven years."
The best investments are made when a team can demonstrate their hypothesis through relatively small clinical trials. As an example, Kate cites Ophthotech, a US company funded by SVLS to develop drugs for ophthalmic diseases, which was able to demonstrate astonishing vision gain in a 22 patient Phase 2a study. "The compelling small trial catapulted the company to raise a large sum to progress a large Phase2b study. It is now worth over $1bn and running pivotal trials," she says. "It's what investors really like. If you need to do a large population study at that early stage, it's just not efficient."
The third major selling point for investors is a management team with demonstrable experience. "Uber smart young people won't be convincing if they have never developed a drug before," Kate says. "It's not enough to just be smart."
Those experienced managers will invariably have spent much of their careers in large pharmaceutical firms, and that brings Kate to what she sees as one of MedCity's fundamental tasks - to communicate the greater south east's rich offer loudly and clearly to international industry and investors.
"Our message to big companies has to be that this region is doing innovative science in a business-friendly environment with regulatory, financial, professional service and clinical trials expertise right on your doorstep," she says. She points to the NHS and its clinical research arm, the National Institute for Health Research, plus projects such as the UK Biobank and 100,000 Genomes as unlike anything else in the world, supporting the sort of in-depth, long-term studies that can only be done in the UK.
"International pharma is already very interested in this region," she says. "We are pushing at an open door.


Our people - Medcity

www.medcityhq.com [cached]

Kate Bingham Managing Partner, SV Life Sciences

Kate Bingham is one of the UK's leading life sciences venture capitalists. She currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Alantos, Auxilium, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, Mednova, Micromet, PowderMed, RespiVert and current investments including Autifony, Bicycle, Convergence, Pulmocide, Oncoethix,TopiVert and VHSquared


The Board | Topivert

www.topivert.com [cached]

Before joining SVLS, Hamish was CEO of Cambridge Antibody Technology (CAT).

...
Kate Bingham (Observer)
Kate is a Managing Partner at SV Life Sciences Advisers, LLC (SVLS). She has been responsible for many successful venture capital investments in biotechnology companies, since joining the firm in 1991. Kate currently serves as a Director of Autifony Therapeutics, Bicycle Therapeutics, Calchan and Convergence Pharmaceuticals. Previously, she worked in business development at Vertex Pharmaceuticals and at Monitor Company. She graduated from Harvard Business School with an MBA, where she was a Baker Scholar, and also holds a first class Masters degree in Biochemistry from the University Oxford.


SV Life Sciences - International Life Sciences Venture Capital Firm

www.svlsa.com [cached]

Kate Bingham

...
Kate Bingham Biotechnology

Similar Profiles

Other People with this Name

Other people with the name Bingham

Melanie Bingham
En Pointe Technologies Inc

Eric Bingham
Pamet Advisors LLC

Austin Bingham
Software House International Inc

Oliver Bingham
Site View Security

Ross Bingham
The City of Calgary

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory